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ABSTRACT
The anti-apoptotic BCL-2 family proteins are important targets for cancer 
chemotherapy. Specific and potent inhibitors of the BCL-2 family, such as ABT-263 
(navitoclax) and ABT-199, are only effective against some members of the BCL-2 
family but do not target MCL-1, which is commonly amplified in tumors and associated 
with chemoresistance. In this report, the selectivity and potency of two putative 
MCL-1 inhibitors, dinaciclib and maritoclax, were assessed. Although both compounds 
induced Bax/Bak- and caspase-9-dependent apoptosis, dinaciclib was more potent 
than maritoclax in downregulating MCL-1 and also in inducing apoptosis. However, 
the compounds induced apoptosis, even in cells lacking MCL-1, suggesting multiple 
mechanisms of cell death. Furthermore, maritoclax induced extensive mitochondrial 
fragmentation, and a Bax/Bak- but MCL-1-independent accumulation of mitochondrial 
reactive oxygen species (ROS), with an accompanying loss of complexes I and III 
of the electron transport chain. ROS scavengers, such as MitoQ, could not salvage 
maritoclax-mediated effects on mitochondrial structure and function. Taken together, 
our data demonstrate that neither dinaciclib nor maritoclax exclusively target MCL-
1. Although dinaciclib is clearly not a specific MCL-1 inhibitor, its ability to rapidly 
downregulate MCL-1 may be beneficial in many clinical settings, where it may reverse 
chemoresistance or sensitize to other chemotherapeutic agents.
INTRODUCTION
Evasion of apoptosis is one of the key hallmarks 
of cancer [1]. Most cancer chemotherapeutic agents kill 
cancer cells by induction of apoptosis through perturbation 
of mitochondria and induction of the intrinsic pathway of 
apoptosis [2, 3]. Major efforts have been made over the 
last decade to develop small molecule inhibitors of the 
anti-apoptotic members of the BCL-2 family of proteins, 
which are highly expressed in some cancers and are 
known to regulate mitochondrial membrane integrity. 
Although development of such inhibitors has proved 
particularly difficult due to the necessity to inhibit protein-
protein interactions, some success has been achieved. 
Most notable is the case of ABT-737 and its orally active 
analogue, ABT-263 (Navitoclax), both of which inhibit 
BCL-2, BCL-XL and BCL-w, whereas a related analogue, 
ABT-199 selectively inhibits BCL-2, and not BCL-XL, 
thus circumventing a dose-limiting thrombocytopenia, 
associated with BCL-XL inhibition [4-10]. Although 
these inhibitors have recently entered clinical trials for 
the treatment of various hematological malignancies, the 
effectiveness of these agents in several cancers is often 
limited by chemoresistance, which has most commonly 
been ascribed to high expression levels of other anti-
apoptotic BCL-2 family members, particularly MCL-1 [7, 
8, 10-15]. Several putative inhibitors of MCL-1 have been 
reported in the literature, although to our knowledge, none 
of the compounds appear to be selective or sufficiently 
potent inhibitors of MCL-1, at least in a cellular context 
[16].
The lower affinity of commonly available BCL-2 
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antagonists to bind and inhibit MCL-1 has been attributed 
to structural differences in the BH3-binding grove of 
MCL-1 compared with other BCL-2 family members. 
Moreover, drugs, such as obatoclax and sabutoclax, that 
have been reported to displace pro-apoptotic BCL-2 
family proteins from MCL-1 lack the specificity to induce 
MCL-1-dependent apoptosis and are more toxic in cellular 
models [9, 16, 17]. Similarly, stapled peptides designed 
to specifically bind the hydrophobic groove of MCL-1 
and mimic BH3-only members are yet to demonstrate 
the desired potency in inducing apoptosis in vivo [18-20]. 
In view of the difficulty in designing a specific MCL-1 
inhibitor, other approaches are being used in particular 
to exploit the known short half-life of MCL-1. Thus, 
cyclin-dependent kinase (CDK) inhibitors, flavopiridol, 
roscovitine and seliciclib, which transcriptionally 
suppress MCL-1, and sorafenib, which diminishes MCL-
1 translation, show some promise [13, 14, 21]. Likewise, 
small molecule inhibitors of deubiquitinases, such as 
USP9X, offer alternative approaches to tackle MCL-1-
mediated chemoresistance [22, 23]. 
In this manuscript, we assess the selectivity and 
potency of two putative MCL-1 inhibitors that inhibit 
MCL-1 by distinct mechanisms. One of these inhibitors is 
marinopyrrole A (maritoclax), which directly binds MCL-
1 and targets it for proteasomal degradation in various 
haematological cancer cells and some melanoma cells 
[24-26]. In contrast, dinaciclib is a broad-spectrum CDK 
inhibitor, and has been shown to downregulate MCL-
1 levels, most likely due to transcriptional repression 
[27-29]. In this study, we show that both dinaciclib and 
maritoclax induce apoptosis in MEFs and non-small 
cell lung cancer (NSCLC) cell lines. While dinaciclib 
is much more potent in downregulating MCL-1 levels, 
MCL-1 loss by maritoclax is relatively modest. The 
induction of apoptosis in a MCL-1-dependent manner 
by both compounds is clearly cell-type specific, as both 
compounds induce apoptosis in MEFs irrespective of 
MCL-1 status. In addition to driving the proteasomal 
turnover of MCL-1, maritoclax also alters the structural 
and functional integrity of mitochondria and leads to the 
accumulation of mitochondrial ROS. 
RESULTS
Dinaciclib and maritoclax induce apoptosis in a 
Bax/Bak- and caspase-9 -dependent manner
Anti-apoptotic members of the BCL-2 family 
regulate mitochondrial integrity in part by sequestering 
their pro-apoptotic counterparts, thereby preventing 
cytochrome c release and subsequent activation of 
caspases in the intrinsic pathway of apoptosis. Small 
molecule inhibitors of the anti-apoptotic BCL-2 family 
members have been designed to release the sequestered 
pro-apoptotic members, which then can induce a Bax/ 
Bak-dependent release of cytochrome c and subsequent 
activation of caspase-9-mediated apoptosis. In this 
study, we use dinaciclib and maritoclax, two structurally 
dissimilar compounds, that antagonize MCL-1 activity 
by distinct mechanisms [24-27, 29, 30]. Substitution 
of the two side chain hydroxyl groups in maritoclax 
with methoxy groups results in an inactive variant, 
dimethoxymaritoclax [31] (Fig. 1A). In MEFs that are 
either wild type, or deficient in Bax and Bak (DKO) or 
caspase-9 (caspase-9 null), both dinaciclib and maritoclax 
induced a concentration-dependent apoptosis in a manner 
that was completely dependent on Bax/ Bak and caspase-9 
(Fig. 1B). However, dinaciclib appeared more potent 
than maritoclax, in inducing apoptosis at nanomolar 
concentrations, whereas concentrations of maritoclax as 
high as 3 µM induced only modest levels of cell death 
(Fig. 1B). The dependence on Bax and Bak to induce 
apoptosis following maritoclax and dinaciclib did not 
persist for more than 24 h, as prolonged exposure (72 h) 
to both maritoclax and dinaciclib resulted in a gradual 
induction of apoptosis even in DKO cells (Fig. 1C).
Dinaciclib and maritoclax induce apoptosis in 
cells that depend on MCL-1 for survival
Since dinaciclib and maritoclax have been shown 
to target MCL-1 synthesis and degradation respectively, 
we examined their efficacy in inducing apoptosis in three 
MCL-1-dependent NSCLC cell lines, H23, H460 and 
H1299 (Figs. 1D-1F). H23 and H460 are dependent on 
MCL-1 for survival [15], whereas H1299 is dependent 
on both MCL-1 and BCL-XL for survival [16]. Therefore, 
we used RNA interference to silence the expression of 
BCL-XL, thus rendering the H1299 cell line solely MCL-
1-dependent. Both dinaciclib and maritoclax caused a 
concentration-dependent induction of apoptosis in the 
NSCLC cell lines, whereas dimethoxymaritoclax failed to 
induce apoptosis, even at 30 µM (Figs. 1D-1F). However 
as in the MEFs, dinaciclib was significantly more potent 
than maritoclax at inducing apoptosis (Figs. 1D-1F). 
Thus the ability to induce apoptosis in several MCL-1-
dependent cell lines supported the hypothesis that both 
dinaciclib and maritoclax targeted MCL-1 and resulted in 
cell death.
Dinaciclib decreases MCL-1 expression levels and 
synergizes with Navitoclax in mediating apoptosis 
Although both dinaciclib and maritoclax induce 
apoptosis in MCL-1-addictive cell lines, the mechanisms 
by which the compounds inhibit MCL-1 are quite distinct. 
In the MCL-1-dependent H460 cells, dinaciclib caused a 
significant reduction of MCL-1 protein levels, as early as 
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2 h and was almost complete at 8 h (Fig. 2A). Dinaciclib 
also resulted in a time-dependent, near-complete loss of 
BIM and NOXA, but the loss of BAK was more modest 
(Fig. 2A). The loss of MCL-1 and its interacting partners 
preceded the cleavage of the canonical caspase substrate, 
poly (ADP-ribose) polymerase (PARP) (Fig. 2A). 
Maritoclax resulted in a much more modest loss of MCL-
1, which, at later time points, was not just restored but 
resulted in protein levels higher than control cells (Fig. 
2A). However, maritoclax also resulted in PARP cleavage 
at 16-24 h (Fig. 2A), suggesting that the early loss of 
MCL-1 was sufficient to trigger apoptotic events in these 
cells. Next, we wished to assess if this early loss of MCL-
1 could synergize with BCL-2 family inhibitors, such as 
navitoclax, which inhibit BCL-2, BCL-XL and BCL-w, but 
not MCL-1, in enhancing apoptosis. For this experiment, 
we used H1299 cells, which depend on BCL-XL and 
MCL-1 for survival [16]. Pretreatment of H1299 cells for 
30 min with navitoclax greatly enhanced the ability of 
dinaciclib to induce apoptosis (Fig. 2B). This potentiation 
of apoptosis was accompanied by the total loss of MCL-
1 and significant PARP cleavage (Figs. 2B and 2C). In 
marked contrast, the extent of apoptosis induction, as 
evidenced by PARP processing and PS externalization, 
in cells exposed to navitoclax and maritoclax, was more 
modest (Figs. 2B and 2C). These observations suggest that 
a complete loss of MCL-1, as observed with dinaciclib, 
may be required to observe synergy with navitoclax.
Figure 1: Dinaciclib and maritoclax induce apoptosis in a Bax/Bak- and caspase-9-dependent manner, and in MCL-
1-dependent cell lines. (A) Chemical structures of dinaciclib, maritoclax and the inactive, dimethoxymaritoclax. (B) MEFs deficient in 
either Bax and Bak (DKO) (dashed lines) or caspase-9 (dotted lines) along with their wild type (WT) counterparts (continuous bold lines) 
were exposed for 24 h to different concentrations of the indicated inhibitors and the extent of apoptosis assessed by phosphatidylserine (PS) 
externalization. (C) WT and DKO MEFs exposed for the indicated times to dinaciclib (100 nM) or maritoclax (10 µM) were assessed for 
apoptosis by PS externalization. (D-F) Three non-small cell lung cancer, MCL-1-dependent, cell lines, (D) H23, (E) H460 and (F) H1299 
cells, reverse-transfected with BCL-XL siRNA for 24 h, were exposed for 24 h to different concentrations of the indicated inhibitors and 
cell death assessed by PS externalization. The blots in the inset reveal the knockdown efficiency of BCL-XL siRNA. Error bars represent 
the Mean ± SEM from three independent experiments. In all the graphs, the extent of apoptosis in untreated control cells matched the % 
apoptosis of the lowest concentration tested for both inhibitors.
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Dinaciclib and maritoclax can induce apoptosis in 
a MCL-1-independent manner
Since dinaciclib and maritoclax induced MCL-1-
dependent apoptosis in the MCL-1-addictive NSCLC 
cell lines, we wished to assess if targeting MCL-1 was 
the predominant mechanism by which these compounds 
induced apoptosis. For this, we used wild type and MCL-
1-deficient MEFs, which do not rely on MCL-1 for 
survival [32]. Dinaciclib (≤ 100 nM) induced similar levels 
of apoptosis in both wild type and MCL-1-deficient MEFs, 
whereas at higher concentrations (> 100 nM), apoptosis 
occurred in a MCL-1-dependent manner (Fig. 2D). These 
results suggested that, at least in MEFs, the majority of 
cell death induced by dinaciclib occurred irrespective of 
MCL-1 status. In marked contrast, maritoclax induced 
more cell death in the MCL-1-deficient than wild type 
MEFs (Fig. 2D), suggesting that although maritoclax 
may preferentially target MCL-1, it clearly can induce 
apoptosis through other mechanisms. To avoid incorrect 
interpretations from possible gene compensation that may 
have occurred following MCL-1 knockdown, we wished 
to confirm these results in MCL-1f/f Rosa-ERCreT2 MEFs, 
in which endogenous MCL-1 undergoes rapid deletion 
following exposure to 4-hydroxytamoxifen (4-HT) [32]. 
Exposure to 4-HT for 24 h was sufficient to deplete MCL-
1 levels in these cells, and the response to dinaciclib was 
Figure 2: Dinaciclib and maritoclax diminish MCL-1 expression levels and induce MCL-1-dependent apoptosis in a 
cell-type specific manner. (A) Whole cell lysates isolated from H460 cells, exposed to dinaciclib (30 nM) or maritoclax (3 µM) for the 
indicated times, were immunoblotted with the indicated antibodies. (B) H1299 cells were exposed to DMSO or ABT-263 (5 µM) for 30 
min, followed for a further 24 h by the indicated concentrations of dinaciclib or maritoclax and cell death assessed by PS externalization. 
Western blots reveal changes in MCL-1 expression and PARP cleavage in H1299 cells, following 24 h of exposure to dinaciclib (30 nM) 
or maritoclax (3 µM), with or without a 30 min pretreatment of ABT-263 (5 µM). (C) Whole cell lysates from H1299 cells exposed to 
dinaciclib (30 nM) or maritoclax (3 µM) for the indicated times were immunoblotted with the indicated antibodies. (D) MEFs deficient 
in MCL-1 (dashed lines) along with their wild type counterparts (continuous bold lines) were exposed for 24 h to the indicated inhibitors 
and apoptosis assessed by PS externalization. (E) MCL-1f/f Rosa-ERCreT2 MEFs were initially exposed to DMSO or 4-hydroxytamoxifen 
(4-HT) (100 nM) to delete endogenous MCL-1. The cells were then exposed for a further 24 h to the indicated inhibitors and apoptosis 
assessed. Western blots reveal changes in MCL-1 expression in different MEFs, following 4-HT exposure for 0, 24 or 48 h. Error bars 
represent the Mean ± SEM from three independent experiments. In all the graphs, the extent of apoptosis in untreated control cells matched 
the % apoptosis of the lowest concentration tested for both inhibitors.
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fairly similar to our previous data in MCL-1-deficient 
MEFs (Fig. 2E). However, maritoclax behaved differently 
in these cells and induced significant cell death even in the 
presence of MCL-1 (Fig. 2E). Taken together, these data 
suggest that dinaciclib and maritoclax, despite causing 
rapid loss of MCL-1, can also induce apoptosis in a MCL-
1-independent manner.
Dinaciclib and maritoclax perturb mitochondria
Although our data in MEFs demonstrated that 
dinaciclib and maritoclax could induce apoptosis in a 
MCL-1-independent manner, these compounds exerted 
apoptosis in a Bax/Bak and caspase-9-dependent manner 
(Fig. 1B). Moreover, dinaciclib and maritoclax caused a 
time-dependent release of cytochrome c (Fig. 3A), with 
a concomitant loss in mitochondrial membrane potential 
(Fig. 3B) and an increase in PS externalization (Fig. 3C). 
As these observations placed the immediate effects of 
dinaciclib and maritoclax at the level of mitochondria, 
we wished to assess if the compounds modulated other 
anti-apoptotic members of the BCL-2 family, which 
may in turn result in apoptosis. In H460 cells, none of 
the anti-apoptotic members such as BCL-2, BCL-XL or 
BCL-w were downregulated following either dinaciclib 
Figure 3: Dinaciclib and maritoclax exert their effects upstream of cytochrome c release and loss in mitochondrial 
membrane potential. (A) H460 cells, grown on coverslips, were exposed for 8 or 16 h to dinaciclib (30 nM) or maritoclax (3 µM), 
stained with the indicated primary and secondary antibodies and subjected to confocal microscopy. Scale bar – 10 µm. (B and C) H460 
cells exposed to dinaciclib (30 nM) or maritoclax (3 µM) for the indicated times were stained with (B) TMRE to monitor changes in 
mitochondrial membrane potential (ϕm) or (C) Annexin V-FITC to assess cell death by measuring PS externalization. Error bars represent 
the Mean ± SEM from three independent experiments. (D) Whole cell lysates from H460 cells, exposed to dinaciclib (30 nM), maritoclax 
(3 µM) or dimethoxymaritoclax (3 µM) for the indicated times, were immunoblotted with the indicated antibodies. Recombinant BFL-1 
protein was used as a positive control for the BFL-1 blot.
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or maritoclax (Fig. 3D). Furthermore, these cells did 
not express detectable levels of BFL-1 (Fig. 3D). Taken 
together, our data revealed that maritoclax and dinaciclib 
may inhibit MCL-1 and induce apoptosis in a cell-type 
specific manner.
Maritoclax, but not dinaciclib, results in extensive 
mitochondrial fragmentation
Although dinaciclib and maritoclax caused a time-
dependent release of cytochrome c (Fig. 3A), our data 
suggested that these compounds might alter mitochondrial 
structure and/ or function, in an analogous manner 
to other putative MCL-1 inhibitors [33]. Exposure to 
maritoclax resulted in rapid mitochondrial swelling, 
which subsequently lead to extensive mitochondrial 
fragmentation (Figs. 4A and 4B). Exposure to dinaciclib 
also resulted in mitochondrial structural changes, although 
these effects were more subtle (Figs. 4A and 4B). 
Maritoclax-mediated mitochondrial structural changes 
accompanied a time-dependent loss both in MFN1 and also 
in the high molecular weight isoforms of OPA1 but did 
not alter DRP1 levels, suggesting a loss in mitochondrial 
fusion (Fig. 4C). Exposure to dinaciclib did not cause 
similar changes in the expression levels of mitochondrial 
fission-fusion proteins (Fig. 4C). Previously, we 
speculated that MCL-1 mediated changes in mitochondrial 
membrane dynamics could possibly exhibit a cross-talk in 
the cell death pathway induced by MCL-1 inhibitors [33]. 
To test our hypothesis, we silenced the expression levels 
of different mitochondrial fission and fusion proteins, and 
assessed the extent of cell death following exposure to 
Figure 4: Maritoclax, and dinaciclib induce marked mitochondrial structural changes, which may contribute 
to apoptosis. (A) H460 cells, grown on coverslips, were exposed for different times to dinaciclib (30 nM), maritoclax (3 µM) or 
dimethoxymaritoclax (3 µM), stained with antibody against HSP60 and subjected to confocal microscopy. Scale bar – 10 µm. (B) At 
least 200 cells from five different fields were quantified for changes in mitochondrial morphology (categorised as filamentous, swollen or 
fragmented) and a graph plotted from three independent replicates. Error bars represent the Mean ± SEM. (C) Whole cell lysates from H460 
cells, exposed to of dinaciclib (30 nM), maritoclax (3 µM) or dimethoxymaritoclax (3 µM) for the indicated times, were immunoblotted 
with the indicated antibodies. (D) H460 cells, reverse-transfected with the indicated siRNA oligoduplexes for 48 h, were exposed for a 
further 24 h to dinaciclib (30 nM) or maritoclax (3 µM), and cell death assessed by PS externalization. Error bars represent the Mean ± 
SEM from three independent experiments. Western blots show the knockdown efficiency of the individual siRNAs. Statistical analysis was 
conducted using a paired t-test (*P < 0.05, ns – not significant, if P > 0.05).
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either maritoclax or dinaciclib. Downregulation of DRP1, 
OPA1 or MFN1 failed to exhibit any positive influence 
on maritoclax or dinaciclib-mediated cell death (Fig. 
4D), whereas silencing of MFN2 was toxic even in the 
absence of the inhibitors and no additive/ synergistic 
effect was observed in combination with either dinaciclib 
or maritoclax (Fig. 4D). These results suggest that MCL-
1 possibly regulates mitochondrial fusion dynamics and 
apoptosis by independent mechanisms, in agreement with 
previous reports [32]. 
Maritoclax but not dinaciclib induces 
mitochondrial ROS 
In addition to its proposed role in regulating 
mitochondrial fusion, MCL-1 is also proposed to 
regulate mitochondrial homeostasis [32]. We therefore 
hypothesized that the dramatic changes in mitochondrial 
ultrastructure should also disrupt mitochondrial function. 
Maritoclax, but not dinaciclib, resulted in a significant 
time-dependent loss of certain components of complexes 
I and III of the electron transport chain (Fig. 5A). Both 
these complexes have been implicated in the generation of 
ROS [34]. Furthermore, maritoclax but not dinaciclib, also 
resulted in a similar depletion of ROMO1 (Fig. 5A), which 
was recently recognized as a sensor for mitochondrial 
ROS [35]. Consistent with these observations, maritoclax 
resulted in a rapid accumulation of mitochondrial 
ROS, as assessed by mitosoxRed staining (Fig. 5B). In 
contrast, exposure to dinaciclib caused little or no build-
up of mitochondrial ROS at the initial time points and an 
increase was only observed at later times (16-24 h) (Fig. 
5B). 
Maritoclax-mediated accumulation of 
mitochondrial ROS, but not membrane 
fragmentation, occurs in a Bax/ Bak-dependent 
manner
Although maritoclax-mediated effects on 
mitochondrial fragmentation and ROS accumulation were 
consistent with the purported roles of MCL-1, we wished 
to assess whether maritoclax induced such changes in a 
Bax/ Bak- and MCL-1- dependent manner. Maritoclax 
induced extensive mitochondrial fragmentation in both 
DKO and MCL-1 null MEFs, to a similar extent as their 
wild type counterparts (Fig. 6A), thus suggesting that 
maritoclax-induced mitochondrial fragmentation occurred 
irrespective of Bax/ Bak and MCL-1 status. In agreement 
with the microscopic observation of mitochondrial 
fragmentation, maritoclax resulted in a loss of high 
molecular weight isoforms of OPA1 in cells that lacked 
either Bax/Bak or MCL-1 (Fig. 6B). However, the loss of 
ETC components observed following maritoclax in wild 
type cells, seem to diminish in the DKO cells, suggesting 
an involvement of Bax/Bak in accelerating maritoclax-
mediated loss of ETC components (Fig. 6B). Maritoclax-
mediated rapid accumulation of mitochondrial ROS also 
occurred in a Bax/Bak-dependent manner, which raised the 
possibility that the mitochondrial ROS were responsible 
for the loss of the ETC components (Fig. 6C). However, 
a similar extent of protection either from the loss of ETC 
components or mitochondrial ROS accumulation was not 
observed in the MCL-1 null MEFs, thus ruling out MCL-1 
Figure 5: Maritoclax induces a loss of different components of the electron transport chain and an accumulation of 
mitochondrial ROS. (A) Whole cell lysates of H460 cells, exposed to dinaciclib (30 nM), maritoclax (3 µM) or dimethoxymaritoclax (3 
µM) for the indicated times, were immunoblotted with the indicated antibodies. (B) H460 cells, exposed to dinaciclib (30 nM) or maritoclax 
(3 µM) for the indicated times, were stained with MitosoxRed to monitor the accumulation of mitochondrial reactive oxygen species 
(ROS). Error bars represent the Mean ± SEM from three independent experiments.
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Figure 6: Maritoclax-mediated mitochondrial effects occur independent of Bax/Bak- and MCL-1. (A) MEFs deficient 
in either Bax/ Bak (DKO) or MCL-1 along with their wild type counterparts were grown on coverslips, exposed for 4 h to maritoclax (10 
µM), stained with antibody against HSP60 and subjected to confocal microscopy. Scale bar – 10 µm. (B) MEFs deficient in either Bax/ Bak 
(DKO) or MCL-1 along with their wild type counterparts exposed to maritoclax (10 µM) for the indicated times, were immunoblotted with 
the indicated antibodies. (C and D) MEFs deficient in either Bax/ Bak (DKO) (C) or MCL-1 (D) along with their wild type counterparts 
were exposed to maritoclax (10 µM) for the indicated times and mitochondrial accumulation of ROS assessed. Error bars represent the 
Mean ± SEM from three independent experiments.
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in these events (Figs. 6B and 6D). Moreover, maritoclax 
induced a greater accumulation of mitochondrial ROS in 
cells lacking MCL-1 (Fig. 6D), similar to the cell death 
effects observed in these cells (Fig. 2D).
MitoQ does not prevent maritoclax-mediated 
mitochondrial effects
To assess if maritoclax-mediated accumulation 
of mitochondrial ROS preceded the loss in complexes 
I and III, we attempted to scavenge mitochondrial ROS 
using MitoQ [36]. Pretreatment with MitoQ (10 µM) 
for 4 hour was necessary to partially rescue the ROS 
(Fig. 7A), which in turn partially prevented the loss of 
NDUFB8 component of complex I (Fig. 7B). No such 
protection was observed against the loss of NDUFA9 
and UQCRC2, as MitoQ appeared to hasten the loss of 
these components, both in the presence and absence of 
maritoclax (Fig. 7B). Moreover, the protective effect of 
MitoQ against the loss of these components was short-
lived, as it failed to sustain its protective effects at later 
times (16 h), both with respect to preventing the loss of 
complexes and in rescuing maritoclax-mediated ROS 
accumulation (Fig. 7B & 7C). In fact, MitoQ appeared 
to enhance the extent of dinaciclib-mediated ROS 
accumulation at 16 h, suggesting that prolonged exposure 
to high concentrations of MitoQ could not mimic the 
protective responses, observed at earlier time points 
(Fig. 7C). The inability of MitoQ to sustain its protective 
effects precluded its valid use to examine the role if 
any of ROS in maritoclax-induced apoptosis. Although 
MitoQ failed to prevent ROS accumulation at later times, 
it was still effective in partially rescuing the effects at 
2 h of exposure to maritoclax (Fig. 7A). Therefore, we 
wished to assess if scavenging maritoclax-mediated ROS 
accumulation could reverse maritoclax-mediated effects 
on mitochondrial structure. Pretreatment with MitoQ not 
only failed to prevent maritoclax-mediated mitochondrial 
swelling and fragmentation, but also resulted in excessive 
mitochondrial fragmentation, on its own, independent of 
maritoclax (Fig. 7D). 
DISCUSSION
Enhanced expression levels of anti-apoptotic BCL-2 
family proteins in several cancers make them promising 
targets for drug therapy. Small molecule inhibitors 
targeting specific members of the BCL-2 family, such 
as navitoclax (BCL-2/BCL-XL/BCL-w) and ABT-199 
(BCL-2 specific) are currently in clinical trials. These 
inhibitors are however ineffective against MCL-1, which 
is commonly amplified in human tumours and associated 
with tumour relapse and chemoresistance. Although 
several reports claiming the discovery of novel inhibitors 
of MCL-1 have been published, to our knowledge, none 
of these inhibitors have demonstrated significant potency 
and/or specificity in a cellular context [16]. In this study, 
we evaluate the potency and specificity of dinaciclib and 
maritoclax, both of which exert MCL-1 inhibition via 
distinct mechanisms [24-26, 29, 30]. Our data indicate that 
both maritoclax and dinaciclib efficiently downregulate 
the expression levels of MCL-1 and induce death in a Bax/
Bak- and caspase-9-dependent manner (Figs. 1 and 2). 
Dinaciclib is a broad-spectrum CDK inhibitor 
and is currently in clinical trials to treat several cancers 
[27,28,37-41]. Owing to its ability to inhibit multiple 
CDKs, dinaciclib could attenuate the expression levels of 
several short-lived proteins, such as MCL-1, which may 
in turn trigger the apoptotic cascade in several cancers. 
Apoptosis mediated by BCL-2 family antagonists is 
believed to result in release of pro-apoptotic members, 
such as BIM and NOXA, which subsequently induce 
apoptosis. In our experiments, dinaciclib decreased the 
expression levels not only of MCL-1 but also of BIM 
and NOXA (Fig. 2). Thus dinaciclib appears to mediate 
apoptosis in a BIM- and NOXA-independent but a Bax/
Bak-dependent manner. Moreover, dinaciclib induced 
apoptosis irrespective of MCL-1 expression levels (Figs. 
2D and 2E), demonstrating that the apoptotic effects 
of dinaciclib can occur in a MCL-1-dependent and 
independent manner and cannot be attributed solely to 
MCL-1 downregulation. 
Although dinaciclib is clearly not a specific MCL-
1 inhibitor, its ability to rapidly downregulate MCL-1 
in several cell types, may clearly be beneficial in many 
clinical settings, where it may reverse chemoresistance or 
sensitize to other chemotherapeutic agents, such as ABT-
199 or navitoclax. Furthermore, the ability of dinaciclib 
to inhibit the transcription of other short-lived proteins, 
which may also regulate cell death, could be beneficial. 
In this regard, dinaciclib is currently in a number of early 
clinical trials either alone or in combination with various 
chemotherapeutic agents including capecitabine, erlotinib, 
carboplatin and bortezomib to evaluate its efficacy in 
various malignancies, including non-small cell lung 
cancer, triple negative breast cancer, pancreatic cancer, 
melanoma, multiple myeloma and refractory chronic 
lymphocytic leukemia [42]. 
Unlike dinaciclib, maritoclax has been shown 
to specifically target MCL-1 for proteasomal 
degradation in experimental models of melanoma and 
various haematological malignancies [24-26]. In our 
studies, maritoclax was not as potent as dinaciclib in 
downregulating MCL-1 and inducing apoptosis (Figs. 1 
and 2). Moreover, the loss of MCL-1 following maritoclax 
was transient in H460 cells, as levels of MCL-1 were even 
elevated at later times through an unknown mechanism 
(Fig. 2A). In contrast, a time-dependent reduction of Mcl-
1 was observed in H1299 cells (Fig. 2C) and MEFs (Fig. 
6B) treated with maritoclax. Maritoclax induced more cell 
death in MEFs deficient in MCL-1 compared with the wild 
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Figure 7: Maritoclax-mediated mitochondrial effects are partially rescued by MitoQ. (A) H460 cells were exposed to 
different concentrations of MitoQ for 4 h, followed by maritoclax (3 µM) for a further 2 h, and mitochondrial accumulation of ROS assessed. 
Statistical analysis was conducted using a paired t-test (*P < 0.05, ns – not significant, if P > 0.05). (B) Whole cell lysates from H460 
cells, exposed to MitoQ (10 µM) for 4 h followed by maritoclax (3 µM) for the indicated times, were immunoblotted with the indicated 
antibodies. (C) H460 cells exposed to MitoQ (10 µM) for 4 h, followed by either Maritoclax (3 µM) or dinaciclib (30 nM) for a further 20 
h were stained with MitosoxRed to monitor changes in mitochondrial ROS accumulation. Error bars represent the Mean ± SEM from three 
independent experiments. (D) H460 cells, grown on coverslips, were exposed for 4 h to MitoQ (10 µM), followed by maritoclax (3 µM) 
for the indicated times. The cells were then immunostained with HSP60 antibody and subjected to confocal microscopy. Scale bar – 10 
µm. (E) Scheme for proposed mechanism of action of dinaciclib and maritoclax. Dinaciclib and maritoclax interfere with the anti-apoptotic 
effects of MCL-1, in a Bax/Bak and caspase-9-dependent manner, by causing the loss of mitochondrial membrane potential (ϕm) and 
activation of mitochondrial outer membrane permeabilization (MOMP), resulting in apoptosis. Maritoclax, but not dinaciclib, interfered 
with other functions of MCL-1, including the postulated regulation of mitochondrial fusion, accompanied by enhanced OPA1 proteolysis 
and loss in MFN1, all of which resulted in mitochondrial structural changes that initially manifested as swelling and subsequently resulted 
in extensive mitochondrial fragmentation. However, maritoclax-mediated changes in mitochondrial structure also occurred in cells lacking 
MCL-1, suggesting the involvement of MCL-1-independent mechanisms in these processes. Maritoclax also resulted in ROS generation 
in mitochondria, which accompanied a loss in several components of the electron transport chain, in a Bax/Bak-dependent but a MCL-1-
independent manner, thus placing Bax/Bak upstream to mitochondrial ROS induction and the loss of ETC components.
Oncotarget11www.impactjournals.com/oncotarget
type MEFs (Fig. 2C), possibly due to its sequestration by 
MCL-1 thereby resulting in less free maritoclax to induce 
apoptosis by other mechanisms. These results suggest 
that the ability of maritoclax to induce Mcl-1-dependent 
apoptosis may be cell type dependent, in agreement with 
a recent report [43]. 
In addition to its conventional role in apoptosis, 
MCL-1 has been implicated in other cellular functions 
ranging from the regulation of ER and mitochondrial 
membrane dynamics to mitochondrial bioenergetics [33, 
44-47]. Inhibitors of MCL-1 have resulted in extensive 
mitochondrial fragmentation and cristae remodelling, 
which have been attributed to a loss of fusion rather than 
enhanced mitochondrial fission [9, 33]. Furthermore, 
accumulation of mitochondrial ROS, a significant 
decrease in ATP production and a near complete loss of 
the components of electron transport chain have all been 
associated with MCL-1 inhibition [32, 33]. Consistent 
with these reports, maritoclax, but not dinaciclib 
interfered with mitochondrial fusion and function (Figs. 
4 and 5), which may be due to the distinct mechanisms 
by which dinaciclib and maritoclax downregulate MCL-
1. However, maritoclax induced extensive mitochondrial 
fragmentation and OPA1 proteolysis even in cells lacking 
MCL-1, suggesting that maritoclax-induced mitochondrial 
fragmentation occurred irrespective of MCL-1 status 
(Fig. 6). Similarly, the loss of ETC components and 
accumulation of mitochondrial ROS also occurred in 
a MCL-1-independent manner, thus confirming that 
maritoclax-mediated mitochondrial changes may not be 
due entirely to MCL-1 downregulation. Nevertheless, 
the loss of ETC components and the rapid accumulation 
of mitochondrial ROS, following maritoclax, occurred 
in a Bax/Bak-dependent manner, thus placing Bax/Bak 
upstream to mitochondrial ROS induction and the loss of 
ETC components.
Moreover, attempts to rescue mitochondrial 
ROS with several ROS scavengers, including SS31, 
N-acetylcysteine, Tiron, Mn(III)TBAP and EUK134 were 
ineffective, and only a partial protection was achieved by 
MitoQ (Fig. 7 and data not shown). Despite the partial 
rescue, MitoQ failed to prevent mitochondrial structural 
and functional changes (Fig. 7). In fact, MitoQ alone, 
resulted in significant mitochondrial fragmentation 
suggesting other off-target effects (Fig. 7D). Therefore 
presently, it is difficult to assess if maritoclax-mediated 
increase in mitochondrial ROS and/or a loss in 
mitochondrial membrane fusion could be directly linked 
to MCL-1 regulated death. Further insights into the 
mechanisms by which MCL-1 regulates these disparate 
functions are required for us to definitely delineate a 
potential crosstalk among these responses (Fig. 7E).
MATERIALS AND METHODS
Cell culture
Wild type and Bax/Bak DKO MEFs from Dr. A. 
Strasser (WEHI, Melbourne, Australia) and caspase-9 null 
MEFs from Prof. T. Mak (University of Toronto, Toronto, 
Canada), MCL-1 deficient and MCL-1f/f Rosa-ERCreT2 
MEFs from Prof. J. Opferman (St Jude Children’s 
Research Hospital, Memphis, TN, USA) were cultured in 
DMEM medium supplemented with 10% fetal calf serum 
(FCS) and 5 mM L-glutamine (all from Life Technologies 
Inc, Paisley, UK). NSCLC cell lines, H23, H460 and 
H1299, from ATCC (Middlesex, UK) were cultured in 
RPMI 1640 medium supplemented with 10% FCS and 5 
mM L-glutamine. 
Reagents
Maritoclax (marinopyrrole A) and 
dimethoxymaritoclax were synthesized with purity >99% 
as previously described [31]. Dinaciclib was obtained 
from Stratech Scientific Ltd (Suffolk, UK). ABT-263 
was obtained from Selleck Chemicals Co. (Houston, TX, 
USA). MitoQ was a kind gift from Prof. M. Jackson, 
University of Liverpool, UK. Antibodies against BIM, 
cleaved PARP, BCL-XL, BCL-w, MFN1 and MFN2 
from Cell Signalling Technology Inc (Danvers, MA, 
USA), BCL-2 from Dako (Ely, UK), BFL-1 (a kind gift 
from Prof. J. Borst, The Netherlands Cancer Institute, 
Amsterdam, The Netherlands), ROMO1 from OriGene 
(Rockville, MD, USA), cytochrome c, DRP1 and OPA1 
from BD biosciences (Oxford, UK), SDHB, UQCRC2, 
MTCO1, and ATPB from Abcam (Cambridge, UK), 
NOXA and tubulin from Calbiochem (Nottingham, UK), 
MCL-1, GAPDH, NDUFA9 and NDUFB8 from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA) and BAK 
from Millipore (Watford, UK) were used. MitosoxRed 
was purchased from Molecular Probes, Inc. (Eugene, OR, 
USA). All other reagents, unless mentioned otherwise, 
were from Sigma-Aldrich Co. (St. Louis, MO, USA). 
siRNA knockdowns and western blotting
Cells were reverse-transfected with 10 nM of BCL-
XL (ID No. s1920), DRP-1 (ID No. s19560), OPA1 (ID 
No. s9850), MFN1 (ID No. s31220) or MFN2 (pool of 
siRNAs) oligoduplexes from either Life Technologies 
Inc. or Santa Cruz Biotechnology using Interferin 
Reagent (Polyplus transfection Inc, NY, USA), according 
to the manufacturer’s protocol and processed 48 h after 
transfection. Western blots were carried out according to 
standard protocols [9]. 
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Flow cytometry and microscopy
Loss in mitochondrial membrane potential (ϕm), 
phosphatidylserine (PS) externalization and mitochondrial 
ROS accumulation were assessed as described previously 
[33,48]. For immunofluorescent staining, cells grown on 
coverslips were fixed with 4% (v/v) paraformaldehyde, 
permeabilized with 0.5% (v/v) Triton X-100 in PBS, 
followed by incubations with antibodies and analyzed, as 
previously described [16]. 
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